Document Detail

Effects of therapeutic concentrations of procainamide on transmembrane action potentials of normal and infarct zone Purkinje fibers and ventricular muscle cells.
MedLine Citation:
PMID:  2484078     Owner:  NLM     Status:  MEDLINE    
Procainamide is a class I antiarrhythmic drug. Most studies of the cellular electrophysiologic effects of procainamide have been done with concentrations well above the therapeutic range. We studied the effects of therapeutic concentrations (10 mg/L) of the drug on transmembrane action potentials recorded from isolated canine cardiac tissues. In normal false tendon Purkinje fibers with maximal diastolic potentials (MDPs) of -93 +/- 1 mV, procainamide decreased action potential duration (APD)-20mV and slightly prolonged APD100%. The dV/dtmax was not decreased. In normal subendocardial Purkinje fibers with MDPs of -92 +/- 1 mV, procainamide 10 mg/L significantly decreased dV/dtmax but did not affect APD-20mV. In normal muscle cells from left ventricular endocardium, procainamide 10 mg/L increased only APD100%. The effects of procainamide on partially depolarized Purkinje fibers varied. In normal subendocardial Purkinje fiber preparations superfused with 7.5 mM KCl-Tyrode's solution, the mean maximal diastolic potentials were -73 +/- 2 mV, and procainamide 10 mg/L slightly decreased action potential amplitude (APA) and increased APD-60mV. In contrast, in 24-h infarct zone Purkinje fibers with MDPs of -75 +/- 4 mV, procainamide 10 mg/L decreased APA and dV/dtmax and prolonged APD100%. In one experiment on an infarct preparation, procainamide also induced 2:1 block at cycle lengths shorter than approximately 400 ms. The results of these experiments indicate that therapeutic concentrations of procainamide exert selective effects on action potentials in partially depolarized zones of infarcted hearts. This action may explain why procainamide can abolish some reentrant arrhythmias.
K H Dangman; D S Miura
Related Documents :
8575508 - Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic acti...
2880678 - Automaticity, triggered activity, and responses to adrenergic stimulation in cat subend...
9659448 - Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic...
1516188 - Declining incidence of ventricular fibrillation in myocardial infarction. implications ...
1513158 - Repair of hypoplastic or interrupted aortic arch via sternotomy.
23528228 - A translational approach in using cell sheet fragments of autologous bone marrow-derive...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  13     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1989 Jun 
Date Detail:
Created Date:  1990-07-26     Completed Date:  1990-07-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  846-52     Citation Subset:  IM    
Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY 10032.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diastole / drug effects
Heart / drug effects*
Heart Conduction System / drug effects*
Heart Ventricles
Membrane Potentials / drug effects
Myocardial Infarction / physiopathology*
Procainamide / administration & dosage,  pharmacology*
Purkinje Fibers / drug effects*
Grant Support
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cyclic nucleotide regulation of neurotransmission in guinea pig mesenteric artery.
Next Document:  Effect of thromboxane antagonism on recanalization during streptokinase-induced thrombolysis in anes...